Corbus Pharmaceuticals Holdings, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products, services, research and therapies.
In the following press release, the company announced “Patient enrollment has commenced in the Phase 2 clinical study of its investigational new drug Resunab™ for the treatment of cystic fibrosis (“CF”). In a pre-clinical CF animal model, Resunab ameliorated inflammation, weight loss, bacterial infection and improved survival.” Read the full article.
Corbus Pharmaceuticals Holdings, Inc. engages in the development and commercialization of novel therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases with clear unmet medical needs. Its product Resunab, is a novel synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. The company was founded in December 2013 and is headquartered in Norwood, MA. [Source: MarketWatch]
Company Website: http://www.corbuspharma.com